Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Forum on Immunopathological Diseases and Therapeutics

ISSN Print: 2151-8017
ISSN Online: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

Buy Issue $224.00 Volume 2, 2011 Issue 1

DOI: 10.1615/ForumImmunDisTher.v2.i1

Table of Contents:

Raf Kinase Inhibitory Protein: A Signal Transduction Modulator and Metastasis Suppressor
Eva M. Eves, Marsha Rich Rosner
pages 13-20
DOI: 10.1615/ForumImmunDisTher.v2.i1.30
Dual Role of RKIP in NF-κB Signaling Pathways
Sungdae Park, Huihui Tang, Kam C. Yeung
pages 21-34
DOI: 10.1615/ForumImmunDisTher.v2.i1.40
Inhibition of STAT3 Activation by RKIP in Colon Cancer
Devasis Chatterjee, Erika L. Moen, Y. Eugene Chin
pages 35-45
DOI: 10.1615/ForumImmunDisTher.v2.i1.50
Locostatin Disrupts Association of Raf Kinase Inhibitor Protein With Binding Proteins by Modifying a Conserved Histidine Residue in the Ligand-Binding Pocket
Anwar B. Beshir, Christian E. Argueta, Lochana C. Menikarachchi, Jose A. Gascon, Gabriel Fenteany
pages 47-58
DOI: 10.1615/ForumImmunDisTher.v2.i1.60
Phosphotyrosine Recognition by the Raf Kinase Inhibitor Protein
Philip C. Simister, Nicholas M. Burton, R. Leo Brady
pages 59-70
DOI: 10.1615/ForumImmunDisTher.v2.i1.70
RKIP Enhances Angiotensin II - Stimulated Signaling
Yasser el Faramawy, Xuebin Fu, Sara H. Agwa, Andreas Langer, Sherif S. Elzahwy, Ursula Quitterer
pages 71-78
DOI: 10.1615/ForumImmunDisTher.v2.i1.80
RKIP-1 and the Cell Cycle: Novel Insight Into Genomic Instability
Fahd Al-Mulla
pages 79-87
DOI: 10.1615/ForumImmunDisTher.v2.i1.90
Role of Raf Kinase Inhibitor Protein in Pathophysiology of Prostate Cancer
Evan T. Keller
pages 89-94
DOI: 10.1615/ForumImmunDisTher.v2.i1.100
Dual Roles of Raf-1 Kinase Inhibitor Protein in the Regulation of Both Tumor Cell Resistance to Apoptotic Stimuli and Epithelial to Mesenchymal Transition
Stavroula Baritaki, Kam C. Yeung, Benjamin Bonavida
pages 95-109
DOI: 10.1615/ForumImmunDisTher.v2.i1.110